Disease Activity Score (DAS)
Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis
8
Long term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open label study of 15 patients
7
Deletion at 2q14 3 is associated with worse response to TNF α blockers in patients with rheumatoid arthritis
7
Attainment and characteristics of clinical remission according to the new ACR EULAR criteria in abatacept treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX) naive patients with Early Erosive rheumatoid arthritis (AGREE)
12
Outcome measures in inflammatory rheumatic diseases
10
Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS)
5
Facet Joints Involvement in Rheumatoid Arthritis: A Cross Sectional Study
8
Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG PET/CT
7
Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City
8
Measuring and monitoring outcomes in undifferentiated and rheumatoid arthritis
205
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study
5
An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS
12
Eligibility criteria for biologic disease modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
8
Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs
6
The prevalence of vertebral fractures in spondyloarthritis: relation to disease characteristics, bone mineral density, syndesmophytes and history of back pain and trauma
8
Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis
11
Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations
8
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2 year follow up of a randomized, non blinded, controlled study
12
Low dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12 month open label randomised study
9
Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long term open label adalimumab treatment: 3 year results of the ABILITY 1 trial
13